Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse

Drug Metabolism and Disposition

Volumn 38, Issue 5, 2010, Pages 761-768

  Rosenquist, Thomas A ^a   Einolf, Heidi J ^b   Dickman, Kathleen G ^a   Wang, Lai ^b   Smith, Amanda ^b   Grollman, Arthur P ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXY 6 NITRO PHENANTHRO (3,4 D) 1,3 DIOXOLO 5 CARBOXYLIC ACID; 8 METHOXY 6 NITRO PHENANTHRO (3,4 D) 1,3 DIOXOLO 5 CARBOXYLIC ACID; ARISTOLOCHIC ACID; CARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DNA ADDUCT; DRUG BIOAVAILABILITY; ENZYME METABOLISM; IN VIVO STUDY; KINETICS; KNOCKOUT MOUSE; LIVER METABOLISM; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

ALBUMINURIA; ANIMALS; ARISTOLOCHIC ACIDS; BIOCATALYSIS; CREATININE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DNA ADDUCTS; GLUCURONIDES; HUMANS; KIDNEY; KINETICS; LIVER; MALE; METABOLIC DETOXICATION, DRUG; METHYLCHOLANTHRENE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MICROSOMES, LIVER; RATS; RECOMBINANT PROTEINS;

MUS; RATTUS; RODENTIA;

EID: 77950936385     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032201     Document Type: Article

References (32)

1. Atanasova SY, von Ahsen N, Toncheva DI, Dimitrov TG, Oellerich M, and Armstrong VW (2005) Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN). Clin Biochem 38:223-228. (Pubitemid 40222320)
2. Attaluri S, Bonala RR, Yang IY, Lukin MA, Wen Y, Grollman AP, Moriya M, Iden CR and Johnson F (2010) DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res 38:339-352.
3. Balachandran P, Wei F, Lin RC, Khan IA, and Pasco DS (2005) Structure activity relationships of aristolochic acid analogues: toxicity in cultured renal epithelial cells. Kidney Int 67:1797-1805. (Pubitemid 40577714)
4. Debelle FD, Vanherweghem JL, and Nortier JL (2008) Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74:158-169.
5. Dong H, Suzuki N, Torres MC, Bonala RR, Johnson F, Grollman AP, and Shibutani S (2006) Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32Ppostlabeling/ polyacrylamide gel electrophoresis analysis. Drug Metab Dispos 34:1122-1127. (Pubitemid 43920871)
6. Gonzalez FJ, Tukey RH, and Nebert DW (1984) Structural gene products of the Ah locus. Transcriptional regulation of cytochrome P1-450 and P3-450 mRNA levels by 3-methylcholanthrene. Mol Pharmacol 26:117-121.
7. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, et al. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 104:12129-12134.
8. Huang F, Clifton J, Yang X, Rosenquist T, Hixson D, Kovac S, and Josic D (2009) SELDI-TOF as a method for biomarker discovery in the urine of aristolochic-acid-treated mice. Electrophoresis 30:1168-1174.
9. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, and Kimura S (1989) Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol 3:1399-1408. (Pubitemid 19241032)
10. Jameson CW, Lunn R, Jeter S, Garner S, Atwood S, Carter G, Levy D and JPC (2008) Background document for aristolochic acid-related exposures, in Report on Carcinogens, 12th ed, pp 1-228, National Toxicology Program, Research Triangle Park, NC.
11. Krumbiegel G, Hallensleben J, Mennicke WH, Rittmann N, and Roth HJ (1987) Studies on the metabolism of aristolochic acids I and II. Xenobiotica 17:981-991.
12. Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, and Schmeiser HH (2004) DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 43:e11-e17.
13. Meinl W, Pabel U, Osterloh-Quiroz M, Hengstler JG, and Glatt H (2006) Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer 118:1090-1097. (Pubitemid 43185594)
14. Mengs U (1988) Tumour induction in mice following exposure to aristolochic acid. Arch Toxicol 61:504-505.
15. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, and Hainaut P (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607-614. (Pubitemid 34556481)
16. 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis 18:1055-1062.
17. Schmeiser HH, Pool BL, and Wiessler M (1986) Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis 7:59-63. (Pubitemid 16184821)
18. Schmeiser HH, Schoepe KB, and Wiessler M (1988) DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 9:297-303.
19. Shibutani S, Bonala RR, Rosenquist T, Rieger R, Suzuki N, Johnson F, Miller F, and Grollman AP (2010) Detoxification of aristolochic acid I by O-demethylation; less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents Int J Cancer doi: 10.1002/ijc.25141.
20. Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, and Grollman AP (2007) Selective toxicity of aristolochic acids I and II. Drug Metab Dispos 35:1217-1222.
21. Sistkova J, Hudecek J, Hodek P, Frei E, Schmeiser HH, and Stiborova M (2008) Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuro Endocrinol Lett 29:733-737.
22. Stiborová M, Frei E, Arlt VM, and Schmeiser HH (2008) Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res 658:55-67. (Pubitemid 351172880)
23. Stiborová M, Frei E, Breuer A, Wiessler M, and Schmeiser HH (2001a) Evidence for reductive activation of carcinogenic aristolochic acids by prostaglandin H synthase-32P-postlabeling analysis of DNA adduct formation. Mutat Res 493:149-160. (Pubitemid 32539438)
24. Stiborová M, Frei E, Hodek P, Wiessler M, and Schmeiser HH (2005a) Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 113:189-197.
25. Stiborová M, Frei E, Sopko B, Sopková K, Marková V, Lanková M, Kumstýrová T, Wiessler M, and Schmeiser HH (2003) Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis 24:1695-1703.
26. Stiborová M, Frei E, Sopko B, Wiessler M, and Schmeiser HH (2002) Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23:617-625. (Pubitemid 34498500)
27. Stiborová M, Frei E, Wiessler M, and Schmeiser HH (2001b) Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem Res Toxicol 14:1128-1137. (Pubitemid 32800169)
28. Stiborová M, Hájek M, Frei E, and Schmeiser HH (2001c) Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH:cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen Physiol Biophys 20:375-392.
29. Stiborová M, Sopko B, Hodek P, Frei E, Schmeiser HH, and Hudecek J (2005b) The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett 229:193-204. (Pubitemid 41429358)
30. Xiao Y, Ge M, Xue X, Wang C, Wang H, Wu X, Li L, Liu L, Qi X, Zhang Y, et al. (2008) Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int 73:1231-1239. (Pubitemid 351693146)
31. Xiao Y, Xue X, Wu YF, Xin GZ, Qian Y, Xie TP, Gong LK, and Ren J (2009) β-Naphthoflavone protects mice from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent mechanism. Acta Pharmacol Sin 30:1559-1565.
32. Xue X, Xiao Y, Zhu H, Wang H, Liu Y, Xie T, and Ren J (2008) Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury. Nephrol Dial Transplant 23:3074-3081.